<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Mbx Biosciences, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock</link>
<description>Latest news and press releases for Mbx Biosciences, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/mbx-biosciences-inc-common-stock" rel="self" type="application/rss+xml" />
<item>
<title>MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-to-host-in-person-and-virtual-obesity-day-on-may-11-2026-to-discuss-expanding-obesity-portfolio</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-to-host-in-person-and-virtual-obesity-day-on-may-11-2026-to-discuss-expanding-obesity-portfolio</guid>
<pubDate>Thu, 23 Apr 2026 12:00:00 GMT</pubDate>
<description>CARMEL, Ind. and BURLINGTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will host an in-person and virtual Obesity Day on Monday, May 11, 2026 at 10:30 a.m. ET to provide an update on its expanding obesity portfolio of products. For more detail</description>
</item>
<item>
<title>MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-reports-inducement-grant-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-reports-inducement-grant-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Fri, 03 Apr 2026 04:00:00 GMT</pubDate>
<description>CARMEL, Ind., April 03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery,</description>
</item>
<item>
<title>Microbix Announces Annual Meeting Voting Results</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/microbix-announces-annual-meeting-voting-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/microbix-announces-annual-meeting-voting-results-1</guid>
<pubDate>Thu, 26 Mar 2026 11:00:00 GMT</pubDate>
<description>MISSISSAUGA, ON / ACCESS Newswire / March 26, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQB:MBXBF) ("Microbix® " or the Company"), a life sciences innovator, manufacturer, and exporter, announces the voting results from the Annual Meeting of Shareholders ...</description>
</item>
<item>
<title>MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-highlights-2</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-highlights-2</guid>
<pubDate>Thu, 12 Mar 2026 12:00:00 GMT</pubDate>
<description>Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated in Q4 2026 Planned nomination of amycretin and GLP-1/GIP/glucagon receptor triple-agonist development candidates for obesity expected in Q2 and Q3 2026 $459.1 million in pro forma cash and investments as of December 31, 2025, including $85.4 million in net proceeds from top-tier i</description>
</item>
<item>
<title>MBX Biosciences Appoints Karen Basbaum as Chief Business Officer</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-appoints-karen-basbaum-as-chief-business-officer</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-appoints-karen-basbaum-as-chief-business-officer</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>CARMEL, Ind., March 10, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery,</description>
</item>
<item>
<title>CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/correcting-and-replacing-mbx-biosciences-announces-successful-end-of-phase-2-fda-meeting-and-provides-phase-3-development-plan-for-once-weekly-canvuparatide-for-hypoparathyroidism</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/correcting-and-replacing-mbx-biosciences-announces-successful-end-of-phase-2-fda-meeting-and-provides-phase-3-development-plan-for-once-weekly-canvuparatide-for-hypoparathyroidism</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026 In the fourth paragraph, we are replacing milligrams with micrograms.</description>
</item>
<item>
<title>MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-announces-successful-end-of-phase-2-fda-meeting-and-provides-phase-3-development-plan-for-once-weekly-canvuparatide-for-hypoparathyroidism</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-announces-successful-end-of-phase-2-fda-meeting-and-provides-phase-3-development-plan-for-once-weekly-canvuparatide-for-hypoparathyroidism</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026 CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc.</description>
</item>
<item>
<title>MBX Biosciences to Participate in Upcoming March Investor Conferences</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-to-participate-in-upcoming-march-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-to-participate-in-upcoming-march-investor-conferences</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>CARMEL, Ind., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery,</description>
</item>
<item>
<title>MBX Biosciences to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-participate-upcoming-investor-130000414</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-participate-upcoming-investor-130000414</guid>
<pubDate>Wed, 11 Feb 2026 13:00:00 GMT</pubDate>
<description>CARMEL, Ind., Feb. 11, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at and participate in the following upcoming investor conferences: 36th Oppenheimer</description>
</item>
<item>
<title>MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-appoints-laurie-stelzer-board-directors-audit-committee-chair-2026-01</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-appoints-laurie-stelzer-board-directors-audit-committee-chair-2026-01</guid>
<pubDate>Thu, 22 Jan 2026 05:00:00 GMT</pubDate>
<description>CARMEL, Ind., Jan. 22, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery,</description>
</item>
<item>
<title>MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-provide-2026-outlook-and-business-update-44th-annual-jp-morgan</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-provide-2026-outlook-and-business-update-44th-annual-jp-morgan</guid>
<pubDate>Sun, 11 Jan 2026 05:00:00 GMT</pubDate>
<description>One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026;</description>
</item>
<item>
<title>MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-present-44th-annual-jp-morgan-healthcare-conference-january-13-2025</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-present-44th-annual-jp-morgan-healthcare-conference-january-13-2025</guid>
<pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
<description>CARMEL, Ind., Dec. 15, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and</description>
</item>
<item>
<title>MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-participate-37th-annual-piper-sandler-healthcare-conference-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-participate-37th-annual-piper-sandler-healthcare-conference-2025-11</guid>
<pubDate>Tue, 18 Nov 2025 05:00:00 GMT</pubDate>
<description>CARMEL, Ind., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and</description>
</item>
<item>
<title>MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-reports-third-quarter-2025-financial-results-and-recent-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-reports-third-quarter-2025-financial-results-and-recent-corporate</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Reported positive topline results from the Phase 2 Avail™ trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering,</description>
</item>
<item>
<title>MBX Biosciences to Participate in November Investor Conferences</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-participate-november-investor-conferences-2025-10-20</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-participate-november-investor-conferences-2025-10-20</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>CARMEL, Ind., Oct. 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and</description>
</item>
<item>
<title>MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-participate-stifel-2025-virtual-cardiometabolic-forum-2025-09-29</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-participate-stifel-2025-virtual-cardiometabolic-forum-2025-09-29</guid>
<pubDate>Mon, 29 Sep 2025 04:00:00 GMT</pubDate>
<description>CARMEL, Ind., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and</description>
</item>
<item>
<title>MBX Biosciences Announces Pricing of Upsized Public Offering</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-announces-pricing-upsized-public-offering-2025-09-25</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-announces-pricing-upsized-public-offering-2025-09-25</guid>
<pubDate>Wed, 24 Sep 2025 04:00:00 GMT</pubDate>
<description>CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and</description>
</item>
<item>
<title>MBX Biosciences Announces Proposed Public Offering</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-announces-proposed-public-offering-2025-09-22</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-announces-proposed-public-offering-2025-09-22</guid>
<pubDate>Mon, 22 Sep 2025 04:00:00 GMT</pubDate>
<description>CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and</description>
</item>
<item>
<title>MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-announces-once-weekly-canvuparatide-achieved-primary-endpoint-phase-2</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-announces-once-weekly-canvuparatide-achieved-primary-endpoint-phase-2</guid>
<pubDate>Mon, 22 Sep 2025 04:00:00 GMT</pubDate>
<description>Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label</description>
</item>
<item>
<title>MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22</title>
<link>https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-provide-topline-results-its-phase-2-trial-potential-once-weekly</link>
<guid isPermaLink="true">https://6ix.com/company/mbx-biosciences-inc-common-stock/news/mbx-biosciences-provide-topline-results-its-phase-2-trial-potential-once-weekly</guid>
<pubDate>Fri, 19 Sep 2025 04:00:00 GMT</pubDate>
<description>CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and</description>
</item>
</channel>
</rss>